FGL1 and metastatic neoplasm: These results indicate that disruption of the TAM/TNFα-OTUD1-FGL1 axis in the liver microenvironment inhibits metastatic tumor progression by activating antitumor immunity, and may synergize with anti-PD-1 therapy.